Mitogen-activated protein kinase 7

Description:

Description
  • Accession: Q13164
  • Swissprot: MK07_HUMAN
  • Organism: Homo sapiens
  • Gene: MAPK7
  • Target class: Kinase

Drug Relations:

bosutinib
a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases Bioactivity details MOA
crizotinib
Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 (c-ros), and Recepteur d'Origine Nantais (RON). Translocations can affect the ALK gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in activation and dysregulation of the gene's expression and signaling which can contribute to increased cell proliferation and survival in tumors expressing these proteins. Crizotinib demonstrated concentration-dependent inhibition of ALK, ROS1, and c-Met phosphorylation in cell-based assays using tumor cell lines and demonstrated antitumor activity in mice bearing tumor xenografts that expressed echinoderm microtubule-associated protein-like 4 (EML4)- or nucleophosmin (NPM)-ALK fusion proteins or c-Met. Bioactivity details MOA
nintedanib
Bioactivity details MOA
sunitinib
An indole and pyrrole derivative that inhibits VEGFR-2 and PDGFR BETA RECEPTOR TYROSINE KINASES. It is used as an antineoplastic agent for the treatment of GASTROINTESTINAL STROMAL TUMORS, and for treatment of advanced or metastatic RENAL CELL CARCINOMA. Bioactivity details MOA